Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Received Approval of XEGLYZE™ (abametapir) Lotion, 0.74%, in the U.S.
Details : XEGLYZE (Abametapir), contains benzyl alcohol. Systemic exposure to benzyl alcohol has been associated with serious and fatal adverse reactions including “gasping syndrome” in neonates and low birth weight infants.
Product Name : Xeglyze
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
